Inari, 1 Kendall Sq, Cambridge, MA 02139, US

Beacon Therapeutics is an ophthalmic gene therapy company based in Cambridge, MA. They are dedicated to saving and restoring the vision of patients with a wide range of prevalent and rare retinal diseases that lead to blindness. Their pioneering ocular gene therapy approach involves modifying a patient's cells by adding a functional copy of the mutated gene responsible for the disease, allowing the body to produce proteins to treat or prevent genetic conditions. With a focus on diseases such as X-Linked Retinitis Pigmentosa, Dry Age-related Macular Degeneration, and Cone Rod Dystrophy, Beacon Therapeutics aims to provide long-lasting benefits and improve the quality of life for patients. Through their bold science and ongoing clinical trials, Beacon Therapeutics offers a real hope for lasting treatments for severe forms of genetic blindness. Their innovative gene therapy approach has shown significant gains in vision in recent studies, providing a glimmer of hope for those affected by these devastating eye diseases. With a commitment to transforming lives and making remarkable happen, Beacon Therapeutics is at the forefront of ocular gene therapy, working towards a future where blindness can be prevented or treated effectively.Generated from the website

Century Bank

Avrobio

Equipoise Therapeutics

Liberty Mutual Insurance